Ehab Dayyat1, Laura D Serpero1, Leila Kheirandish-Gozal1, Julie L Goldman2, Ayelet Snow1, Rakesh Bhattacharjee1, David Gozal3. 1. Department of Pediatrics, Division of Sleep Medicine and Kosair Children's Hospital Research Institute, University of Louisville, Louisville, KY. 2. Department of Surgery, Division of Sleep Medicine and Kosair Children's Hospital Research Institute, University of Louisville, Louisville, KY; Department of Pediatrics, Division of Sleep Medicine and Kosair Children's Hospital Research Institute, University of Louisville, Louisville, KY. 3. Department of Pediatrics, Division of Sleep Medicine and Kosair Children's Hospital Research Institute, University of Louisville, Louisville, KY. Electronic address: dgozal@peds.bsd.uchicago.edu.
Abstract
INTRODUCTION: The abundant expression of leukotrienes (LTs) and their receptors in adenotonsillar tissues of children with obstructive sleep apnea (OSA) suggest that LT antagonists could be useful in treating OSA. METHODS: The effects of LTD4 and of LT receptor antagonists zileuton, montelukast, and BAY u9773 were examined on mixed cell cultures prepared from dissociated tonsils or adenoids harvested intraoperatively from children with polysomnographically diagnosed OSA. Proliferation was assessed by (3)[H]-thymidine incorporation, and inflammatory cytokine production (tumor necrosis factor [TNF]-alpha, interleukin [IL]-6, IL-8, IL-10, and IL-12) was assessed in supernatants using enzyme-linked immunosorbent assay. RESULTS: LTD4 elicited dose-dependent increases in adenotonsillar cell proliferation (p < 0.001; n = 12). All LT antagonists exhibited dose-dependent reductions in adenotonsillar cellular proliferation rates, with montelukast more than BAY u9773 more than zileuton (n = 14/group; p < 0.001). However, BAY u9773 showed partial agonist effects and increased cellular proliferation at higher concentrations (10(-4) mmol/L; p < 0.01; n = 12). LTD4 effects were partially blocked by montelukast and BAY u9773 but not by zileuton. All three antagonists reduced TNF-alpha, IL-6, and IL-12 concentrations, with selective changes in IL-8 and no effects on IL-10 levels. CONCLUSIONS: LT pathways mediate intrinsic proliferative and inflammatory signaling pathways in adenotonsillar tissues from children with OSA, and targeted pharmacologic disruption of these pathways may provide nonsurgical alternatives for prevention and treatment of this disease.
INTRODUCTION: The abundant expression of leukotrienes (LTs) and their receptors in adenotonsillar tissues of children with obstructive sleep apnea (OSA) suggest that LT antagonists could be useful in treating OSA. METHODS: The effects of LTD4 and of LT receptor antagonists zileuton, montelukast, and BAY u9773 were examined on mixed cell cultures prepared from dissociated tonsils or adenoids harvested intraoperatively from children with polysomnographically diagnosed OSA. Proliferation was assessed by (3)[H]-thymidine incorporation, and inflammatory cytokine production (tumor necrosis factor [TNF]-alpha, interleukin [IL]-6, IL-8, IL-10, and IL-12) was assessed in supernatants using enzyme-linked immunosorbent assay. RESULTS: LTD4 elicited dose-dependent increases in adenotonsillar cell proliferation (p < 0.001; n = 12). All LT antagonists exhibited dose-dependent reductions in adenotonsillar cellular proliferation rates, with montelukast more than BAY u9773 more than zileuton (n = 14/group; p < 0.001). However, BAY u9773 showed partial agonist effects and increased cellular proliferation at higher concentrations (10(-4) mmol/L; p < 0.01; n = 12). LTD4 effects were partially blocked by montelukast and BAY u9773 but not by zileuton. All three antagonists reduced TNF-alpha, IL-6, and IL-12 concentrations, with selective changes in IL-8 and no effects on IL-10 levels. CONCLUSIONS: LT pathways mediate intrinsic proliferative and inflammatory signaling pathways in adenotonsillar tissues from children with OSA, and targeted pharmacologic disruption of these pathways may provide nonsurgical alternatives for prevention and treatment of this disease.
Authors: Jie Zhu; Yu-Sheng Qiu; David J Figueroa; Venkata Bandi; Helen Galczenski; Kaoru Hamada; Kalpalatha K Guntupalli; Jilly F Evans; Peter K Jeffery Journal: Am J Respir Cell Mol Biol Date: 2005-08-25 Impact factor: 6.914
Authors: Yuen-yu Lam; Eric Y T Chan; Daniel K Ng; Chung-hong Chan; Josephine M Y Cheung; Shuk-yu Leung; Pok-yu Chow; Ka-li Kwok Journal: Chest Date: 2006-12 Impact factor: 9.410
Authors: Harold Nelson; James Kemp; William Berger; Jonathon Corren; Thomas Casale; Louise Dube; Karen Walton-Bowen; Nicole LaVallee; Miganush Stepanians Journal: Ann Allergy Asthma Immunol Date: 2007-08 Impact factor: 6.347
Authors: A Faith; M H Fernandez; J Caulfield; T-K Loke; C Corrigan; B O'Connor; T H Lee; C M Hawrylowicz Journal: Allergy Date: 2008-02 Impact factor: 13.146
Authors: Anthony J Grady; Jane S Hankins; Brent Haberman; Robert Schoumacher; Rose Mary Stocks Journal: Sleep Breath Date: 2017-01-11 Impact factor: 2.816
Authors: Stephanie O Zandieh; Amarilis Cespedes; Adam Ciarleglio; Wallace Bourgeois; David M Rapoport; Jean-Marie Bruzzese Journal: J Asthma Date: 2016-10-14 Impact factor: 2.515
Authors: Abdelnaby Khalyfa; Sina A Gharib; Jinkwan Kim; Ehab Dayyat; Ayelet B Snow; Rakesh Bhattacharjee; Leila Kheirandish-Gozal; Julie L Goldman; David Gozal Journal: Am J Respir Crit Care Med Date: 2010-01-21 Impact factor: 21.405